Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026)

Vireo Growth's (VREOF) quarterly Total Non-Current Liabilities came in at $604.7 million in Q1 2026, up 166.89% year-on-year from $226.6 million in Q1 2025, and up 19.08% quarter-over-quarter from $507.8 million in Q4 2025.

Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Vireo Growth has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $604.7 million for Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $604.7 million, up 166.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $604.7 million (up 166.89% YoY), and the FY2025 annual result was $507.8 million, up 127.41% from the prior year.
  • Total Non-Current Liabilities came in at $604.7 million for Q1 2026 at Vireo Growth, up from $507.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $604.7 million in Q1 2026 to a low of $155.7 million in Q4 2022.
  • The 5-year median for Total Non-Current Liabilities is $217.0 million (2024), against an average of $287.1 million.
  • Across the five-year window, Total Non-Current Liabilities grew 6.23% in 2025 and surged 166.89% in 2026, its largest moves.
  • Vireo Growth's Total Non-Current Liabilities stood at $155.7 million in 2022, then advanced by 27.92% to $199.2 million in 2023, then grew by 12.11% to $223.3 million in 2024, then soared by 127.41% to $507.8 million in 2025, then grew by 19.08% to $604.7 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $604.7 million (Q1 2026), $507.8 million (Q4 2025), and $432.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 18.28 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 11.64 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 599.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 44.12 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 1.24 Bn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 6.26 Bn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 2.44 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 1.81 Bn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 1.13 Bn
10 Vireo Growth - - 59.30 Mn 604.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 604.70 Mn
Dec 31, 2025 507.80 Mn
Sep 30, 2025 432.61 Mn
Jun 30, 2025 389.44 Mn
Mar 31, 2025 226.57 Mn
Dec 31, 2024 223.30 Mn
Sep 30, 2024 204.87 Mn
Jun 30, 2024 217.04 Mn
Mar 31, 2024 213.28 Mn
Dec 31, 2023 199.19 Mn
Sep 30, 2023 184.29 Mn
Jun 30, 2023 173.66 Mn
Dec 31, 2022 155.71 Mn
Sep 30, 2021 110.17 Mn
Jun 30, 2021 52.73 Mn
Mar 31, 2021 58.01 Mn